UNSPSC 51431614: Verapamil hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C27H38N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V3888OEY5R, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile but more generally known as verapamil hydrochloride, which bears US NIH Compound Identifier 2520. European Medicines Agency schedules Verapamil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05088MIG.

UNSPSC 51431614 Verapamil hydrochloride is a Commodity code covering a single active pharmaceutical ingredient supplied to state and local health systems, emergency services, and pharmacy benefit programs. State and local governments procure verapamil and related cardiovascular agents as components of Advanced Life Support medication inventories, formulary stocking for health plans and state health agencies, and multi-source generic pharmaceutical contracts serving participating jurisdictions. Issuing bodies include municipal fire and rescue departments, state health and human services agencies administering pharmacy benefits, and multi-state cooperative purchasing alliances aggregating demand across participating state and local members. The procurement mix spans direct goods purchases from vendors and manufacturers through sealed-bid competitions, requests for information from state pharmacy programs exploring direct-to-manufacturer relationships, and master agreements with generic pharmaceutical manufacturers serving cooperative purchasing networks.

Recent activity concentrates in Florida and Minnesota, with supplemental activity in Texas. The City of Tampa's Purchasing Department posted IFB 26-P-00188 in April 2026 for Advanced Life Support Medications, including diltiazem, labetalol, adenosine, and epinephrine for Tampa Fire Rescue, with a due date of April 8, 2026 and an estimated contract value of $40,000.00, featuring a 5 percent Small Local Business Enterprise bid discount and one-year contract term with two optional one-year renewals. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products with a response deadline of March 26, 2026; vendors must supply through three authorized wholesalers, maintain pricing in multiple formats, and comply with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs, signaling early-stage exploration of alternative contracting models for pharmacy benefit management outside traditional PBM and GPO channels.